Sanofi India Ltd
Sanofi India Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Sanofi India is targeting sustainable and profitable growth particularly through its insulin portfolio, including brands such as Toujeo, Soliqua, and Lantus. The company is focusing on sustainable and profitable growth with a customer-centric, digitally empowered model.
From Sanofi India Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sanofi India is targeting sustainable and profitable growth particularly through its insulin portfolio, including brands such as Toujeo, Soliqua, and Lantus.
- Growth is expected from expanding market reach, especially into Tier 2 and Tier 3 cities, facilitated by partnerships that leverage partners’ distribution capabilities.
- Partnerships are anticipated to deliver gradual growth over time, not immediate spikes, with an expected moderate increase in domestic sales (about 2% growth in some segments).
- Export revenues, which decreased due to past divestments, are projected to partially recover with new markets like Russia and South Africa contributing.
- New product launches are planned but not expected before 2026; focus remains on accelerating uptake of recently launched products like Soliqua.
2 more points from Sanofi India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanofi India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The focus is on transformation and modernization of the business model, including digital empowerment and AI integration.
- There is emphasis on operational excellence, partnership models, and optimizing existing manufacturing capabilities (e.g., increasing volume at Goa site).
- The company is exploring business cases for new product launches, but nothing confirmed for the near term.
- Key focus areas remain on growth through partnerships, AI adoption, and expanding diabetes and insulin portfolio rather than heavy capital investments.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanofi India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sanofi India Ltd said on order book & pipeline — free account, 30 seconds.
Sanofi India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹438 Cr, net profit ₹84 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanofi India Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanofi India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanofi India Ltd Q2 FY26 results?
Sanofi India is targeting sustainable and profitable growth particularly through its insulin portfolio, including brands such as Toujeo, Soliqua, and Lantus. The company is focusing on sustainable and profitable growth with a customer-centric, digitally empowered model.
What is Sanofi India Ltd share price analysis?
Sanofi India Ltd currently shows a neutral. The stock trades at a P/E of 21.8 with a market cap of ₹7,468 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sanofi India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.